Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.39 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | PAM | P19021 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265505 | 0.89 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HTR2ASIGMAR1 | |
| SCHEMBL12970937 | 0.89 | CHRM2 (0.51) | CHRM2CHRM1CHRM3HTR2ASIGMAR1 | |
| SCHEMBL5168468 | 0.89 | CHRM2 (0.51) | CHRM2CHRM1CHRM3HTR2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL4107880 | 0.87 | CHRM2 (0.50) | CHRM2CHRM1CHRM3HTR2ASIGMAR1 | |
| Water SCHEMBL7807739 | 0.87 | CHRM2 (0.50) | CHRM2CHRM1CHRM3HTR2ASIGMAR1 | |
| Water SCHEMBL8679126 | 0.87 | CHRM2 (0.50) | CHRM2CHRM1CHRM3HTR2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL8197750 | 0.87 | CHRM2 (0.50) | CHRM2CHRM1CHRM3HTR2ASIGMAR1 | |
| SCHEMBL2744951 | 0.78 | HTR2A (0.50) | HTR2ASIGMAR1CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL27506988 | 0.73 | HTR2A (0.46) | CHRM2CHRM1CHRM3HTR2ASIGMAR1 | |
| Ammonia Solution, Strong SCHEMBL27572180 | 0.72 | CHRM2 (0.49) | CHRM2CHRM1CHRM3CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-1467995-B1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-2162452-A1 | SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2008147314-A1 | SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1467995-A4 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1467995-A2 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003053361-A2 | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | CHRM2 133/4885CHRM1 156/4885CHRM3 126/4885 |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, OXER1, CNR1 | CHRM2 353/4885CHRM1 224/4885CHRM3 295/4885 |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | HRH3, HRH2, HRH4 | CHRM2 224/4885CHRM1 510/4885CHRM3 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.